182 related articles for article (PubMed ID: 1350457)
1. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
Berns EM; Klijn JG; van Staveren IL; Portengen H; Noordegraaf E; Foekens JA
Eur J Cancer; 1992; 28(2-3):697-700. PubMed ID: 1350457
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
Berns EM; Foekens JA; van Putten WL; van Staveren IL; Portengen H; de Koning WC; Klijn JG
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):13-9. PubMed ID: 1356012
[TBL] [Abstract][Full Text] [Related]
3. Analysis of oncogenes and tumor suppressor genes in human breast cancer.
Yamashita H; Kobayashi S; Iwase H; Itoh Y; Kuzushima T; Iwata H; Itoh K; Naito A; Yamashita T; Masaoka A
Jpn J Cancer Res; 1993 Aug; 84(8):871-8. PubMed ID: 8104920
[TBL] [Abstract][Full Text] [Related]
4. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Berns EM; Foekens JA; van Staveren IL; van Putten WL; de Koning HY; Portengen H; Klijn JG
Gene; 1995 Jun; 159(1):11-8. PubMed ID: 7607564
[TBL] [Abstract][Full Text] [Related]
5. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
6. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
7. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis.
Ottestad L; Andersen TI; Nesland JM; Skrede M; Tveit KM; Nustad K; Børresen AL
Acta Oncol; 1993; 32(3):289-94. PubMed ID: 8100712
[TBL] [Abstract][Full Text] [Related]
8. The significance of oncogene amplification in primary breast cancer.
Seshadri R; Matthews C; Dobrovic A; Horsfall DJ
Int J Cancer; 1989 Feb; 43(2):270-2. PubMed ID: 2563720
[TBL] [Abstract][Full Text] [Related]
9. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
10. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene amplification and human breast tumor phenotype.
Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
[TBL] [Abstract][Full Text] [Related]
12. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis.
Børresen AL; Ottestad L; Gaustad A; Andersen TI; Heikkilä R; Jahnsen T; Tveit KM; Nesland JM
Br J Cancer; 1990 Oct; 62(4):585-90. PubMed ID: 1977466
[TBL] [Abstract][Full Text] [Related]
13. Oncogene amplification per se: an independent prognostic factor in human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mol Carcinog; 1994 Dec; 11(4):189-91. PubMed ID: 7999260
[TBL] [Abstract][Full Text] [Related]
14. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
Machotka SV; Garrett CT; Schwartz AM; Callahan R
Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995
[TBL] [Abstract][Full Text] [Related]
15. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer.
Berns EM; Klijn JG; Henzen-Logmans SC; Rodenburg CJ; van der Burg ME; Foekens JA
Int J Cancer; 1992 Sep; 52(2):218-24. PubMed ID: 1325950
[TBL] [Abstract][Full Text] [Related]
16. A paradigm for oncogene complementation in human breast cancer.
Roux-Dosseto M; Martin PM
Res Virol; 1989; 140(6):571-91. PubMed ID: 2694252
[TBL] [Abstract][Full Text] [Related]
17. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.
Seshadri R; Firgaira FA; Horsfall DJ; McCaul K; Setlur V; Kitchen P
J Clin Oncol; 1993 Oct; 11(10):1936-42. PubMed ID: 8105035
[TBL] [Abstract][Full Text] [Related]
19. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc.
Henry JA; Hennessy C; Levett DL; Lennard TW; Westley BR; May FE
Int J Cancer; 1993 Mar; 53(5):774-80. PubMed ID: 8449602
[TBL] [Abstract][Full Text] [Related]
20. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
